Halozyme 扩大与 argenx 的合作，推进 ENHANZE 技术

will receive royalties on net sales of products using ENHANZE ® .

including facilitating more convenient administration and dosing regimens of injectable medications through subcutaneous delivery

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1....

Halozyme is headquartered in San Diego, CA

ENHANZE ® has touched more than one million patient lives

through ten commercialized products

Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids

it has expanded its global collaboration and license agreement with argenx

across over 100 global markets

Halozyme also develops, manufactures and commercializes drug-device combination products

"We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "The addition of two new exclusive targets further va…

SAN DIEGO , Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE ® with two additional exclusive…